• Proceedings of the KAIS Fall Conference
• /
• 2001.05a
• /
• pp.292-294
• /
• 2001

Cystocin is identified from the screening of Streptomyces sp GCA0001. It is isolated from the culture of streptomyces sp GCA0001. A white coloured cystocin is structurally similar to puromycin, an antibiotic produced by streptomyces albonrger. Like puromycin, cystocin possesses an antibacterial, antitumour and antiviral activity. It impairs the protein synthesis by inhibiting polypeptide chain elongation.

• Archives of Pharmacal Research
• /
• v.26 no.6
• /
• pp.446-448
• /
• 2003

Cystocin belongs to the class of nucleoside antibiotics from Streptomyces sp. GCA0001. Cystocin showed good activity against Gram-positive bacteria, but showed less activity against the Gram-negative bacteria. Cystocin exhibited about two to four folds higher activity than puromycin. Especially, cystocin shows relatively strong activity against Streptococcus strains. Cystocin shows quite potent antitumor activity against all of the cells tested showing $IC_{50}$ values of 0.10 to 0.14 $\mu$ g/mL. This in vitro result indicates that the cytotoxocity of cystocin is two ten folds more active than puromycin s.

• Journal of Microbiology and Biotechnology
• /
• v.13 no.4
• /
• pp.483-486
• /
• 2003

3'-[S-Methyl-cysteinyl]-3'-amino-3'-deoxy-N,N- dimethyl adenosine, cystocin, is a biosynthesized antibiotic material newly identified from Streptomyces sp. GCA0001. Its structure was found to be similar to puromycin, where the terminal tyrosine is replaced by a methyl cysteine. NMR data prove that the 3-ammo ribose is connected to dimethylaminopurine through the anomeric carbon at 1'-carbon. The methyl cysteinyl unit is connected to the amino unit of ribose by peptide bond. The verification of the structure was performed by comparing the puromycin nucleosides resulted from the hydrolysis of cystocin and puromycin, respectively. Antibiotic activity of cystocin against Streptococcus was found to be two times more potent than that of puromycin.

• Proceedings of the KAIS Fall Conference
• /
• 2001.05a
• /
• pp.295-297
• /
• 2001

Cystocin, a derivative of Puromycin, is a new material derived from Streptomyces sp GCA0001, new strain of Actinomycetes spiecies. This compound has outstanding biological activities in anti-bacteria, anti-tumor and anti-virus than former Puromycin compounds. And it is chosen by natural selection processing through extraction, isolation and purification from , so it may replace old Puromycins in most applications.